Back to News
Market Impact: 0.2
Q32 Bio Inc. Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Earnings
Q32 Bio reported $289.6 million in cash and cash equivalents as of September 30, 2026. The company said this cash balance was sufficient, but the available article text does not specify the period it is expected to cover or provide further financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
QTTB0.10
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- A blue wave sends futures into the green
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT